{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T20:15:38Z","timestamp":1781554538659,"version":"3.54.5"},"reference-count":39,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2021,7,7]],"date-time":"2021-07-07T00:00:00Z","timestamp":1625616000000},"content-version":"unspecified","delay-in-days":6,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004348","name":"Stockholms L\u00e4ns Landsting","doi-asserted-by":"publisher","award":["20180120"],"award-info":[{"award-number":["20180120"]}],"id":[{"id":"10.13039\/501100004348","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001862","name":"The Swedish Research Council","doi-asserted-by":"crossref","award":["2019-01034"],"award-info":[{"award-number":["2019-01034"]}],"id":[{"id":"10.13039\/501100001862","id-type":"DOI","asserted-by":"crossref"}]},{"name":"The Ragna and Paul Nyberg Foundation","award":["Not applicable"],"award-info":[{"award-number":["Not applicable"]}]},{"name":"The King Gustaf V\u2019s and Queen Victoria\u2019s Freemasons\u2019Foundation","award":["Not applicable"],"award-info":[{"award-number":["Not applicable"]}]},{"DOI":"10.13039\/501100003793","name":"Hj\u00e4rt-Lungfonden","doi-asserted-by":"publisher","award":["20190478"],"award-info":[{"award-number":["20190478"]}],"id":[{"id":"10.13039\/501100003793","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003793","name":"Hj\u00e4rt-Lungfonden","doi-asserted-by":"publisher","award":["20200163"],"award-info":[{"award-number":["20200163"]}],"id":[{"id":"10.13039\/501100003793","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003793","name":"Hj\u00e4rt-Lungfonden","doi-asserted-by":"publisher","award":["20200505"],"award-info":[{"award-number":["20200505"]}],"id":[{"id":"10.13039\/501100003793","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open Resp Res"],"accepted":{"date-parts":[[2021,5,15]]},"published-print":{"date-parts":[[2021,7]]},"abstract":"<jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Tumour necrosis factor \u03b1 (TNF-\u03b1) is pivotal in sarcoid granuloma formation, and inhibitors of TNF-\u03b1 offer an attractive third-line treatment option in sarcoidosis. The sarcoid inflammation is characterised by an exaggerated T helper 1 response, and evidence indicates a contribution of dysregulated and\/or deficient NK (natural killer) cells, CD56+ T\u2009cells and B cells.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>Insight into how TNF-\u03b1 inhibitors influence these cells may provide more information on inflammatory mechanisms in sarcoidosis and improve understanding of such treatment. We therefore evaluated treatment effects of the TNF-\u03b1 inhibitor infliximab on lung and peripheral blood (PB) NK, CD56+ T\u2009cells and B cells.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Fifteen patients were assessed with PB samples, spirometry and CT scan, and 11 of them also underwent bronchoalveolar lavage (BAL) close to start of infliximab treatment. These investigations were repeated after 6\u2009months of treatment.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Twelve out of 15 patients disclosed a clinical improvement at follow-up. Median percentage of BAL fluid (BALF) CD56+ T\u2009cells increased while a decrease was seen in PB (p&lt;0.05\u2009and 0.005, respectively). No significant changes were observed for NK cells. There was a trend towards increased median percentage of PB B cells (p=0.07), and a negative correlation was observed between PB and BALF B cells after treatment (p&lt;0.05).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>In conclusion, 6\u2009months of infliximab treatment in patients with sarcoidosis, of whom the majority benefited from the treatment, influenced immune cells in the lung and circulation differently, highlighting the importance of investigating several compartments concomitantly when evaluating treatment effects on the inflammatory activity.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/bmjresp-2021-000933","type":"journal-article","created":{"date-parts":[[2021,7,7]],"date-time":"2021-07-07T13:48:14Z","timestamp":1625665694000},"page":"e000933","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":3,"title":["Effects of infliximab on lung and circulating natural killer cells, CD56+ T cells and B cells in sarcoidosis"],"prefix":"10.1136","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2844-4773","authenticated-orcid":false,"given":"Susanna","family":"Kullberg","sequence":"first","affiliation":[{"name":"Department of Respiratory Medicine, Theme Inflammation and Ageing, Karolinska University Hospital, Stockholm, Sweden"},{"name":"Respiratory Medicine Division, Department of Medicine, Karolinska Institute, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia V","family":"Rivera","sequence":"additional","affiliation":[{"name":"Respiratory Medicine Division, Department of Medicine, Karolinska Institute, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Grunewald","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Theme Inflammation and Ageing, Karolinska University Hospital, Stockholm, Sweden"},{"name":"Respiratory Medicine Division, Department of Medicine, Karolinska Institute, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders","family":"Eklund","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Theme Inflammation and Ageing, Karolinska University Hospital, Stockholm, Sweden"},{"name":"Respiratory Medicine Division, Department of Medicine, Karolinska Institute, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2021,7,7]]},"reference":[{"key":"2025083110481848000_8.1.e000933.1","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-019-0096-x"},{"key":"2025083110481848000_8.1.e000933.2","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/j.semarthrit.2018.10.005","article-title":"Anti-Tumor necrosis factor agents in sarcoidosis: a systematic review of efficacy and safety","volume":"48","author":"Adler","year":"2019","journal-title":"Semin Arthritis Rheum"},{"key":"2025083110481848000_8.1.e000933.3","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00055213"},{"key":"2025083110481848000_8.1.e000933.4","first-page":"91","article-title":"Practical eminence and experience-based recommendations for use of TNF-\u03b1 inhibitors in sarcoidosis","volume":"31","author":"Drent","year":"2014","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"2025083110481848000_8.1.e000933.5","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1111\/cei.13438","article-title":"Changes in lung immune cells related to clinical outcome during treatment with infliximab for sarcoidosis","volume":"201","author":"Kullberg","year":"2020","journal-title":"Clin Exp Immunol"},{"key":"2025083110481848000_8.1.e000933.6","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.05.00030805"},{"key":"2025083110481848000_8.1.e000933.7","first-page":"185","article-title":"Exaggerated TNFalpha release of alveolar macrophages in corticosteroid resistant sarcoidosis","volume":"19","author":"Ziegenhagen","year":"2002","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"2025083110481848000_8.1.e000933.8","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1002\/cyto.b.20120","article-title":"Prognostic value of neutrophils and NK cells in bronchoalveolar lavage of sarcoidosis","volume":"70","author":"Tutor-Ureta","year":"2006","journal-title":"Cytometry B Clin Cytom"},{"key":"2025083110481848000_8.1.e000933.9","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.00892"},{"key":"2025083110481848000_8.1.e000933.10","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2567.2001.01248.x"},{"key":"2025083110481848000_8.1.e000933.11","doi-asserted-by":"publisher","DOI":"10.1016\/S0047-6374(00)00199-8"},{"key":"2025083110481848000_8.1.e000933.12","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1183\/09031936.06.00129505","article-title":"Increasing level of CD56+ T-cells in peripheral blood in sarcoidosis","volume":"27","author":"Naccache","year":"2006","journal-title":"Eur Respir J"},{"key":"2025083110481848000_8.1.e000933.13","doi-asserted-by":"publisher","DOI":"10.1172\/JCI110036"},{"key":"2025083110481848000_8.1.e000933.14","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00224513"},{"key":"2025083110481848000_8.1.e000933.15","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0043588"},{"key":"2025083110481848000_8.1.e000933.16","doi-asserted-by":"crossref","first-page":"2833","DOI":"10.1007\/s10067-018-4183-2","article-title":"Significant elevation of the levels of B-cell activating factor (BAFF) in patients with sarcoidosis","volume":"37","author":"Ando","year":"2018","journal-title":"Clin Rheumatol"},{"key":"2025083110481848000_8.1.e000933.17","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.174.9.5537"},{"key":"2025083110481848000_8.1.e000933.18","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.173.2.807"},{"key":"2025083110481848000_8.1.e000933.19","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0043644"},{"key":"2025083110481848000_8.1.e000933.20","first-page":"149","article-title":"ATS\/ERS\/WASOG statement on sarcoidosis. American thoracic Society\/European respiratory Society\/World association of sarcoidosis and other granulomatous disorders","volume":"16","author":"Hunninghake","year":"1999","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"2025083110481848000_8.1.e000933.21","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0009088"},{"key":"2025083110481848000_8.1.e000933.22","first-page":"535","article-title":"Systemic immune response of patients with active pulmonary sarcoidosis","volume":"61","author":"Baughman","year":"1985","journal-title":"Clin Exp Immunol"},{"key":"2025083110481848000_8.1.e000933.23","doi-asserted-by":"publisher","DOI":"10.1136\/ard.60.8.750"},{"key":"2025083110481848000_8.1.e000933.24","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.04-0792"},{"key":"2025083110481848000_8.1.e000933.25","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.163.7.2005028"},{"key":"2025083110481848000_8.1.e000933.26","doi-asserted-by":"crossref","DOI":"10.1186\/s12890-019-0802-1","article-title":"Nk and NKT cells in the diagnosis of diffuse lung diseases presenting with a lymphocytic alveolitis","volume":"19","author":"Sokhatska","year":"2019","journal-title":"BMC Pulm Med"},{"key":"2025083110481848000_8.1.e000933.27","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s00408-013-9527-8","article-title":"Activated CD8(+) T cells and NKT cells in BAL fluid improve diagnostic accuracy in sarcoidosis","volume":"192","author":"T\u00f8ndell","year":"2014","journal-title":"Lung"},{"key":"2025083110481848000_8.1.e000933.28","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s10238-019-00578-3","article-title":"Nk and NKT-like cells in granulomatous and fibrotic lung diseases","volume":"19","author":"Bergantini","year":"2019","journal-title":"Clin Exp Med"},{"key":"2025083110481848000_8.1.e000933.29","doi-asserted-by":"publisher","DOI":"10.1038\/nri2904"},{"key":"2025083110481848000_8.1.e000933.30","doi-asserted-by":"publisher","DOI":"10.1513\/pats.200606-130MS"},{"key":"2025083110481848000_8.1.e000933.31","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.rmed.2009.11.008","article-title":"Deficiency of pulmonary Valpha24 Vbeta11 natural killer T cells in corticosteroid-na\u00efve sarcoidosis patients","volume":"104","author":"Korosec","year":"2010","journal-title":"Respir Med"},{"key":"2025083110481848000_8.1.e000933.32","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2249.2012.04626.x"},{"key":"2025083110481848000_8.1.e000933.33","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-57741-0","article-title":"Imbalance in B cell and T follicular helper cell subsets in pulmonary sarcoidosis","volume":"10","author":"Kudryavtsev","year":"2020","journal-title":"Sci Rep"},{"key":"2025083110481848000_8.1.e000933.34","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.05118-11"},{"key":"2025083110481848000_8.1.e000933.35","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2008.03.003"},{"key":"2025083110481848000_8.1.e000933.36","doi-asserted-by":"publisher","DOI":"10.1165\/rcmb.2002-0164PS"},{"key":"2025083110481848000_8.1.e000933.37","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0160103","article-title":"B-Cell dysregulation in Crohn's disease is partially restored with infliximab therapy","volume":"11","author":"Timmermans","year":"2016","journal-title":"PLoS One"},{"key":"2025083110481848000_8.1.e000933.38","doi-asserted-by":"crossref","first-page":"574-580","DOI":"10.1016\/j.dld.2020.11.030","article-title":"B-Cell activating factor (BAFF) expression is associated with Crohn's disease and can serve as a potential prognostic indicator of disease response to infliximab treatment","volume":"53","author":"Andreou","year":"2021","journal-title":"Dig Liver Dis"},{"key":"2025083110481848000_8.1.e000933.39","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-201270"}],"container-title":["BMJ Open Respiratory Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjresp-2021-000933","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,31]],"date-time":"2025-08-31T17:48:31Z","timestamp":1756662511000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopenrespres.bmj.com\/lookup\/doi\/10.1136\/bmjresp-2021-000933"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,7,7]]},"published-print":{"date-parts":[[2021,7]]}},"alternative-id":["10.1136\/bmjresp-2021-000933"],"URL":"https:\/\/doi.org\/10.1136\/bmjresp-2021-000933","relation":{},"ISSN":["2052-4439"],"issn-type":[{"value":"2052-4439","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7]]}}}